Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: treatment

  • The Silent Epidemic: Hepatitis C Virus

    Hepatitis C accounts for a significant burden of disease. There are many barriers to the eradication of hepatitis C virus (HCV), from infection identification to treatment, making it a very complex public health concern. Unfortunately, no vaccine for HCV exists yet, and development proves difficult because of the overwhelming genetic diversity. HCV can be treated by a patient’s primary care physician; this group is instrumental in screening for and treating hepatitis C.

  • Mifepristone as a Treatment Option for Adenomyosis

    This multicenter, placebo-controlled, double-blind randomized clinical trial was conducted in 10 hospitals in China and enrolled 134 patients with diagnosed adenomyosis to evaluate mifepristone as an effective treatment for adenomyosis pain symptoms. Among the intervention group, 98.1% had total remission of adenomyosis pain symptoms as well as improved secondary outcomes with no serious adverse events. Mifepristone is promising for treating pain from adenomyosis.

  • Berdazimer Topical Gel (Zelsuvmi)

    The U.S. Food and Drug Administration has approved the first and only prescription drug for the home treatment of molluscum contagiosum. Berdazimer, administered with a hydrogel, is a nitric oxide-releasing agent with antiviral properties.

  • Do Patients with Heart Failure Feel Better on Dapagliflozin?

    An analysis of the DETERMINE studies of dapagliflozin vs. placebo in patients with heart failure showed some improvement in self-reported symptoms in those with reduced ejection fraction on dapagliflozin but not in the six-minute walk test. No improvements in symptoms or physical activity levels were found in those with preserved ejection fraction on dapagliflozin.

  • The Best Treatment for Heavy Menstrual Bleeding

    This randomized controlled trial among 62 individuals compared the 52-mg levonorgestrel intrauterine device to combined oral contraceptives for heavy menstrual bleeding and found that, in the intention-to-treat analyses, there was no significant difference in Menstrual Bleeding Questionnaire scores at six months or 12 months (mean difference, 2.5; 95% confidence interval [CI], -10.0, 5.0; and mean difference, -1.1; 95% CI, -8.7, 6.5, respectively).

  • What Is the Best First-Line Treatment for Young Women with Generalized Epilepsy?

    Valproate is a highly efficacious drug for treating idiopathic generalized epilepsy (IGE) but is not an option for many young women because of known teratogenic risks. This retrospective, multicenter study examined women with IGE who were treated initially with either levetiracetam or lamotrigine monotherapy, demonstrating superior efficacy of levetiracetam, although exclusively in women with juvenile myoclonic epilepsy.

  • The IP Role in Sepsis

    The Centers for Disease Control and Prevention has issued core elements for hospital sepsis programs, calling for a multidisciplinary team to prevent, detect, and treat these life-threatening systemic breakdowns.

  • Treatable Causes of Rapidly Progressive Dementias

    Many cases of rapidly progressive dementia are caused by prion diseases and have no effective treatments. But, with the greater awareness of the presentation for autoimmune encephalitis, these disorders make up an increasing percentage of presenting cases and can be aggressively and successfully treated. The STAM3P score helps to identify potentially treatable cases of this disorder.

  • Malaria in Pregnancy — Simplified Treatment Decisions

    History, data, and international consensus lead to the same conclusion: Artemether-lumefantrine is the first choice for treatment of uncomplicated falciparum malaria in everyone, even pregnant women.

  • Malaria in Pregnancy — Simplified Treatment Decisions

    History, data, and international consensus lead to the same conclusion: Artemether-lumefantrine is the first choice for treatment of uncomplicated falciparum malaria in everyone, even pregnant women.